Journal of Parkinsons Disease

Papers
(The median citation count of Journal of Parkinsons Disease is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
When Parkinson's disease interferes in a couple's life: A qualitative study90
Acknowledgment to reviewers 202587
Feasibility and potential effectiveness of an exergame program for people with moderate to advanced Parkinson's disease: A pilot randomized controlled trial84
A prospective analysis of falls in Parkinson's disease: Does physical capacity moderate the relationship between walking amount and falls rates?78
Evolution of disease modifying therapy clinical trial design and therapeutic endpoints for Parkinson's disease74
Levodopa-Induced dyskinesia in Latin America: Prevalence and associated clinical factors in the LARGE-PD cohort63
A framework to standardize gait study protocols in Parkinson's disease63
Clinical Trial Highlights: Modulators of Mitochondrial Function62
This is NOT the End for Immunotherapy in Parkinson’s Disease – A Perspective from Early Drug Development Scientists61
Chronotropic Incompetence in Parkinson’s Disease: A Possible Marker of Severe Disease Phenotype?57
Creation of a machine learning-based model for early identification of mild cognitive impairment risk in Parkinson's disease: A PD research center-based population study55
One world, one goal: Advocacy and policy for a unified Parkinson's response55
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease54
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression53
Impact and management of cognition on speech and swallow function in Parkinson's disease46
Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention44
Is There an Association Between Parkinson’s Disease and Periodontitis? A Systematic Review and Meta-Analysis43
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson’s Disease42
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease41
Clinical Trial Highlights – Aerobic Exercise for Parkinson’s Disease41
Effects of Very Low- and High-Frequency Subthalamic Stimulation on Motor Cortical Oscillations During Rhythmic Lower-Limb Movements in Parkinson’s Disease Patients38
May Bradykinesia Features Aid in Distinguishing Parkinson’s Disease, Essential Tremor, And Healthy Elderly Individuals?37
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease34
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders34
Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”34
Reply to the Letter to the Editor: Stefani A, “Is it too early to Underrate Genetic onto PD Pathogenesis? Reflections on History”34
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson’s Disease Care Pathway: A Healthcare Improvement Initiative33
Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease32
Post-Traumatic Stress Disorder and Risk of Parkinson’s Disease in a Veteran Cohort31
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review31
A possible pathway to freezing of gait in Parkinson's disease30
Rapid Voluntary Blinking as a Clinical Marker of Parkinson’s Disease30
The fixel GI Parkinson's research and integrated support model (PRISM)30
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder28
A monoclonal antibody-based immunoassay reinforces DOPA decarboxylase in cerebrospinal fluid as a diagnostic biomarker for Parkinson's disease with potential prognostic value28
Longitudinal change in swallow function in patients with Parkinson's disease (PD)28
Anxiety is associated with increased risk of suicidality in Parkinson's disease28
Are Preformed Fibrils a Model of Parkinson’s Disease?28
What medicines do people with Parkinson's disease want?28
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease27
Taste Impairments in a Parkinson’s Disease Model Featuring Intranasal Rotenone Administration in Mice26
Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy26
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies25
Feasibility and Proof-of-Concept of Delivering an Autonomous Music-Based Digital Walking Intervention to Persons with Parkinson’s Disease in a Naturalistic Setting24
Burden, Anxiety, and Depression Among Caregivers of Parkinson’s Disease Patients24
Nomogram for Early Prediction of Parkinson’s Disease Based on microRNA Profiles and Clinical Variables24
Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson’s Disease on Brain Networks24
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease24
Metabotropic Glutamate Receptor 4 (mGlu 4 ) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia23
DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson’s Disease23
The Role of Diet in Parkinson’s Disease23
Home-Based time-constrained reactive training enhances movement speed in upper and lower limbs in Parkinson's disease: A randomized controlled trial23
Burden of tremor in Parkinson's disease: A survey study22
Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease22
Metabolic connectivity of freezing in Parkinson's disease22
Mortality and causes of death in patients with Parkinson's disease in Taiwan22
Telerehabilitation for early-stage Parkinson's disease: A randomized controlled feasibility trial of individualised real-time physiotherapy delivered via a videoconference platform21
Twenty-five-year experience with apomorphine pump in Parkinson's disease: A real-life long-term retrospective tolerance study20
Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay20
Modulation of Cerebellar Oscillations with Subthalamic Stimulation in Patients with Parkinson’s Disease20
Motor Memory Consolidation Deficits in Parkinson’s Disease: A Systematic Review with Meta-Analysis20
Effects of Low-Intensity Vestibular Noise Stimulation on Postural Instability in Patients with Parkinson’s Disease20
Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain20
Acknowledgment to Reviewers 202220
Symmetric and Profound Monoaminergic Degeneration in Parkinson’s Disease with Premotor REM Sleep Behavior Disorder19
Hidden Gems in Neurology: The Syndrome of Hemiparkinsonism-Hemiatrophy19
A glimpse of the end-of-life of people with Parkinson's disease and atypical parkinsonism: A descriptive analysis of electronic health records19
Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson’s Disease?19
Atypical parkinsonian syndromes in French Guiana: Similarities and differences with Caribbean variants19
Gait Declines Differentially in, and Improves Prediction of, People with Parkinson’s Disease Converting to a Freezing of Gait Phenotype19
Effects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease19
Enhancing the diagnostic potential of electroretinography in Parkinson's disease: A review of protocol and cohort criteria18
“Tip-of-the-Tongue” Phenomenon in Parkinson’s Disease: A Hidden Gem18
Specialized Allied Health Care for Parkinson’s Disease: State of the Art and Future Directions18
Non-Pharmacological Interventions for People with Parkinson’s Disease: Are We Entering a New Era?18
Sex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis18
Enhancing Trial Delivery in Parkinson’s Disease: Qualitative Insights from PD STAT18
A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults18
Unveiling the neural network of freezing of gait in Parkinson's disease: A coordinate-based network study17
Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life17
Georgina M. Aldridge, Matthew Weber and Lauren Walker recipients of the Parkinson Prize 202517
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease17
Reactive astrocyte-related pathogenic genes in Parkinson's disease: A multi-omics Mendelian randomization study17
Utility of a newly created questionnaire on subtle motor symptoms in high-risk subjects with Parkinson's disease17
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?16
Parkinson’s Pals: A Student-Led Program to Facilitate Intergenerational Connections and Promote Psychosocial Well-Being Among Persons with Parkinson’s Disease16
Freezing of gait detection: The effect of sensor type, position, activities, datasets, and machine learning model16
Anxiety-related attentional characteristics and their relation to freezing of gait in people with Parkinson's: Cross-validation of the Adapted Gait Specific Attentional Profile (G-SAP)16
Tackling Parkinson’s Disease as a Global Challenge16
Buspirone regulates cortico-striatal gamma oscillations to ameliorate dyskinesia16
Enhancing Participant Engagement in Clinical Studies: Strategies Applied in the Personalized Parkinson Project16
Structural-Functional Correlates of Response to Pedunculopontine Stimulation in a Randomized Clinical Trial for Axial Symptoms of Parkinson’s Disease16
Anxiety in Parkinson’s Disease Is Associated with Changes in Brain Structural Connectivity15
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease15
A Practical Guide to the Evaluation of Compensation Strategies for Gait Impairment in Parkinson’s Disease15
Integrating virtual reality into multidisciplinary care for Parkinson's disease: A narrative review15
40-Year Incidence of Early-Onset Parkinson’s Disease in Southeast Minnesota15
Non-Pharmacological Treatment of Autonomic Dysfunction in Parkinson’s Disease and Other Synucleinopathies14
Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson’s Disease14
Reduced Thickness of the Retina in de novo Parkinson’s Disease Shows A Distinct Pattern, Different from Glaucoma14
Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson’s Disease14
Place of death in Parkinson's disease: A systematic review and meta-analysis of associated factors14
Gender Distribution in Deep Brain Stimulation for Parkinson’s Disease: The Effect of Awake versus Asleep Surgery14
Remote Delivery of Allied Health Therapies in Parkinson’s Disease14
Designing the First Trials for Parkinson’s Prevention14
Discontinuation or acute unplanned cessation of oral dopaminergic medications in persons with Parkinson's disease: A practice review13
Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease13
Inflammasome Activation in Parkinson’s Disease13
Spinal Cord Stimulation for Gait Disorders in Parkinson’s Disease13
Natural Health Products for Symptomatic Relief of Parkinson’s Disease: Prevalence, Interest, and Awareness13
Feasibility and acceptability of PDConnect, a multi-component intervention to support physical activity in people with Parkinson's disease: A mixed methods study13
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?13
Prevalence of Concomitant Pathologies in Parkinson’s Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms13
Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson’s Disease Patients13
Kinematic Effects of Combined Subthalamic and Dorsolateral Nigral Deep Brain Stimulation in Parkinson’s Disease13
Discordance between actual and perceived balance ability relates to quality of life and global cognition in a clinical sample of Parkinson patients13
Distinct Patterns of Gene Expression Changes in the Colon and Striatum of Young Mice Overexpressing Alpha-Synuclein Support Parkinson’s Disease as a Multi-System Process13
Advice to People with Parkinson’s in My Clinic: Orthostatic Hypotension13
Stem cell treatments and Parkinson's disease: Science and misconceptions12
Diffuse putaminal degeneration without iron deposition in multiple system atrophy12
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation12
Depressive symptoms can negatively influence patient reported disease severity after subthalamic nucleus stimulation for Parkinson's disease12
Mycobacterium bovis Infection of a Deep Brain Stimulation System Following Intravesical Bacillus Calmette-Guérin (BCG) Instillation12
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease12
New insights from a Malaysian real-world deep brain stimulation cohort12
Obstructive sleep apnea, periodic limb movements, and REM sleep without atonia are common in Parkinson's disease and correlate with motor symptom burden12
Pediatric-onset PRKN disease: New insights into an understudied population12
Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson’s Disease12
Echocardiographic insights into cardiovascular autonomic dysfunction in Parkinson's disease12
Analysis of α-synuclein seed amplification assay in carriers of GBA1 and LRRK2 pathogenic variants12
Non-Pharmacological Interventions for Depression and Anxiety in Parkinson’s Disease11
Association Between Body Mass Index Changes and All-Cause Mortality in Parkinson’s Disease11
Therapeutic Strategies for Immune Transformation in Parkinson’s Disease11
Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease11
Relating movement behaviours and non-motor characteristics in people with Parkinson's disease: A compositional data analysis approach11
Infections and Changes in Commensal Bacteria and the Pathogenesis of Parkinson’s Disease11
How Information Affects Patients with Parkinson’s Disease: A Scoping Review of the Literature11
Pain Fluctuations in Parkinson’s Disease and Their Association with Motor and Non-Motor Fluctuations11
Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study11
The potential of distributed diagnostics for the early detection of Parkinson's disease11
The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson’s Disease11
The impact of diet on Parkinson's disease risk: A data-driven analysis in a large Italian case-control population11
Dopaminergic Cell Replacement for Parkinson’s Disease: Addressing the Intracranial Delivery Hurdle11
Assessing the Role of Locus Coeruleus Degeneration in Essential Tremor and Parkinson’s Disease with Sleep Disorders11
RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions11
Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials11
Risk of Neurodegeneration in Patients with Rapid Eye Movement Sleep Behavior Disorder11
Biofluid Detection of Pathological α -Synuclein in the Prodromal Phase of Synucleinopathies11
Preparing for Parkinson’s disease prevention trials: Current progress and future directions11
Acknowledgment to Reviewers 202311
Increasing trends in utilization of physical and occupational therapy services in early Parkinson's disease10
Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease10
Parkinson's disease drug therapies in the clinical trial pipeline: 2015–202410
A PLAN to address the Parkinson pandemic10
Screening Tools for Sarcopenia in Mild to Moderate Parkinson’s Disease: Assessing the Accuracy of SARC-F and Calf Circumference10
Why the Gut Microbiome Must Be Considered When Evaluating the Impact of Pesticides on Parkinson’s Disease Risk10
Mucuna pruriens in untreated Parkinson's disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial10
Motor outcomes in unilateral, bilateral rapid, and bilateral delayed staging deep brain stimulation for Parkinson’s disease10
Disease Progression of Data-Driven Subtypes of Parkinson’s Disease: 5-Year Longitudinal Study from the Early Parkinson’s Disease Longitudinal Singapore (PALS) Cohort10
Letter to the Editor: Is It Too Early to Underrate Genetics onto PD Pathogenesis? Reflections on History10
Oscillation-Specific Nodal Differences in Parkinson’s Disease Patients with Anxiety10
Quantitative measures of total and phosphorylated alpha-synuclein in skin tissue as potential biomarkers for synucleinopathies10
Colonoscopy and Subsequent Risk of Parkinson’s Disease10
Parkinson's disease participant-led research on the impact of deep brain stimulation frequency10
Development of a Screening Tool for Assessing Sexual Difficulties Among Patients with Parkinson’s Disease: The PD-SDS10
Novel insights into relationships between metabolic covariance patterns of FDG-PET data and clinical status in Parkinson's disease using partial least squares correlation analysis10
Machine Learning-Based Classification of Parkinson’s Disease Patients Using Speech Biomarkers10
Worsening of Parkinson’s Disease After Termination of COVID-19 Quarantine Cannot Be Reversed Despite Resumption of Physiotherapy10
Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms10
Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials10
Surface electromyographic profiles during gait initiation in people with Parkinson's disease: The effects of external sensory cueing9
Declining trends in the incidence of Parkinson's disease: A cohort study in Germany9
Advances in sex-specific single-cell transcriptomic profiling in Parkinson's disease9
Early bone health assessment is indicated in Parkinson's: Risk factor analysis in a UK population-based cohort study9
Addressing the “Replication Crisis” in the Field of Parkinson’s Disease9
Fear of Progression is Determined by Anxiety and Self-Efficacy but not Disease-Specific Parameters in Patients with Parkinson’s Disease: Preliminary Data from a Multicenter Cross-Sectional Study9
PARKinSOUND: Impact of participation in an orchestra in patients with Parkinson's disease9
The Impact of Motor, Non-Motor, and Social Aspects on the Sexual Health of Men Living with Parkinson’s Disease9
Evaluation and management of male sexual dysfunction in Parkinson's disease: A clinical road map9
The central cholinergic system as a therapeutic target in Parkinson's disease9
Sleep Disorders in Early-Onset Parkinsonism: A Population-Based Study9
Lactobacillaceae and Parkinson's disease: An apparent paradox9
Association Between Menopausal Hormone Therapy and Risk for Parkinson’s Disease9
Concordance between imaging and clinical based STN-DBS programming improves motor outcomes of directional stimulation in Parkinson's disease9
Commentary: Pesticides and GBA1 pathogenic variants in Parkinson's disease: An emerging and potentially dangerous association9
Factors Associated with Preferred Place of Care and Death in Patients with Parkinson’s Disease: A Cross-Sectional Study9
Immunogenetic Determinants of Parkinson’s Disease Etiology9
Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder8
Neural Oscillations and Functional Significances for Prioritizing Dual-Task Walking in Parkinson’s Disease8
Reading Difficulties in Parkinson’s Disease: A Stepped Care Model for Neurovisual Rehabilitation8
Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson’s Disease8
Pupil-light reflex in early-stage Parkinson's disease8
Diverse preferences, different solutions: Exploring remote monitoring preferences in Parkinson's disease through a discrete choice experiment8
An Evaluation of KELVIN, an Artificial Intelligence Platform, as an Objective Assessment of the MDS UPDRS Part III8
Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson’s Disease8
A Randomized, Double-Blinded Crossover Trial of Short Versus Conventional Pulse Width Subthalamic Deep Brain Stimulation in Parkinson’s Disease8
Clinical Trial Highlights – Interventions Promoting Physical Activity in Parkinson’s Disease8
Visualization of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Results8
Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson’s Disease8
Neuropsychiatric Symptoms and Caregiver Stress in Parkinson’s Disease with Cognitive Impairment, Alzheimer’s Disease, and Frontotemporal Dementia8
Hidden Gems in the Neurological Literature of Progressive Supranuclear Palsy8
The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease8
Pilot Study Results Assessing the Accuracy of a Ballistic Sleep Monitor Relative to Polysomnography in Parkinson’s Disease7
Cognition and Other Non-Motor Symptoms in an At-Risk Cohort for Parkinson’s Disease Defined by REM-Sleep Behavior Disorder and Hyposmia7
Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop7
Advice to people with Parkinson's in my clinic: Get a cardiopulmonary exercise test7
Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson’s Disease7
Opportunities and Pitfalls of REM Sleep Behavior Disorder and Olfactory Dysfunction as Early Markers in Parkinson’s Disease7
A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease7
The Importance of Digital Health Literacy in an Evolving Parkinson’s Disease Care System7
The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson’s Disease7
Self-delivered arousal-heightening stimuli to improve mobility in persons with parkinsonism: A case series7
Tackling gender in progressive supranuclear palsy: Male patients present more apathy7
Gaps in the Parkinson's disease therapeutic clinical pipeline: A focus on approaches targeting disease pathobiology7
Pathophysiology and pharmacological management for sleep problems in Parkinson's disease7
Body-First Subtype of Parkinson’s Disease with Probable REM-Sleep Behavior Disorder Is Associated with Non-Motor Dominant Phenotype7
Considerations on How to Prevent Parkinson’s Disease Through Exercise7
mHealth-assisted expiratory muscle strength training in Parkinson's disease patients: A proof-of-concept study7
Association Between Parkinson’s Disease and Coronary Artery Disease: A Systematic Review and Meta-Analysis7
The Etiology of Parkinson’s Disease: New Perspectives from Gene-Environment Interactions7
When caution becomes neglect: Deep brain stimulation and cognitive impairment in Parkinson's disease7
Fear of progression in Parkinson's disease: Role of age and occupational status6
Corrigendum to “Parkinsonian Hand or Clinician’s Eye? Finger Tap Bradykinesia Interrater Reliability for 21 Movement Disorder Experts”6
A Retrospective Comparison of Multiple Approaches to Anatomically Informed Contact Selection in Subthalamic Deep Brain Stimulation for Parkinson’s Disease6
The Cause and Duration of Emergency Admissions to Hospital in People with Idiopathic Parkinson’s Disease, Under the Care of a UK Service, During the First Year of the COVID-19 Pandemic6
Seeds of hope: Mucuna Pruriens offers promise for persons with Parkinson's disease in Africa6
Parkinson's disease associated with LRRK2 -R1441C mutation: Characterization and comparison with other LRRK2 6
Risk Factors for Postoperative Delirium Severity After Deep Brain Stimulation Surgery in Parkinson’s Disease6
Apathy linked to higher amyloid burden and cognitive deterioration in Parkinson's disease6
Recognition, management, and patient perspectives of impulsive-compulsive disorders in Parkinson’s disease6
Pain and the Non-Pharmacological Management of Pain in People with Parkinson’s Disease6
Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial6
Cost-Effectiveness Analyses of Non-Pharmacological and Non-Surgical Interventions in Idiopathic Parkinson’s Disease: A Systematic Review6
Autopallidotomy: From Colloquial Term to Scientific Theory6
Consensus expert recommendations for management of dysphagia during hospital admission in Parkinson's disease6
Advice to people with Parkinson's in my clinic: How to manage running-induced dystonia6
Is motor reserve associated with a rapid progression of Parkinson disease?6
Visual hallucinations in Parkinson's disease are associated with deficits in social perception6
Pointing in the right direction: Greater motor improvements with directional versus circular subthalamic nucleus deep brain stimulation for Parkinson's disease6
Digital Intervention Promoting Physical Activity in People Newly Diagnosed with Parkinson’s Disease: Feasibility and Acceptability of the Knowledge, Exercise-Efficacy and Participation (KEEP) Interven6
New Journal Section: Hidden Gems from the Literature of Parkinson’s Disease6
Alcohol and Parkinson’s Disease: A Systematic Review and Meta-Analysis6
Exploring the Complex Phenotypes of Impaired Finger Dexterity in Mild-to-moderate Stage Parkinson’s Disease: A Time-Series Analysis6
A Randomized Controlled Trial of Fecal Microbiota Transplantation for Parkinson’s Disease: Getting it right, if not PARFECT6
Molecular Mechanisms Mediating the Transfer of Disease-Associated Proteins and Effects on Neuronal Activity6
Gut microbial shifts toward inflammation in Parkinson's disease: Insights from pilot shotgun metagenomics Egyptian cohort6
The future of clinical trials? Monitoring mobility as an outcome measure in Parkinson's disease: The mobilise-D study6
“ To Bean or Not to Bean ”: Therein lie the hype and the hope. Advice to people with Parkinson in my clinic about Mucuna pruriens<6
Dopamine-responsive post-anoxic parkinsonism6
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease6
0.24908900260925